Seamus Fernandez
Stock Analyst at Guggenheim
(3.78)
# 675
Out of 4,868 analysts
99
Total ratings
54.41%
Success rate
7.39%
Average return
Main Sectors:
Stocks Rated by Seamus Fernandez
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CDTX Cidara Therapeutics | Maintains: Buy | $35 → $50 | $21.31 | +134.63% | 3 | May 16, 2025 | |
| LLY Eli Lilly and Company | Maintains: Buy | $973 → $928 | $785.03 | +18.21% | 15 | Apr 14, 2025 | |
| MBX MBX Biosciences | Reiterates: Buy | $44 | $10.28 | +328.02% | 2 | Apr 10, 2025 | |
| ARQT Arcutis Biotherapeutics | Reiterates: Buy | n/a | $13.67 | - | 3 | Apr 3, 2025 | |
| VERV Verve Therapeutics | Reiterates: Buy | n/a | $11.12 | - | 2 | Mar 25, 2025 | |
| PCVX Vaxcyte | Reiterates: Buy | $160 | $33.41 | +378.90% | 4 | Mar 12, 2025 | |
| MTSR Metsera | Initiates: Buy | $56 | $27.71 | +102.09% | 1 | Feb 25, 2025 | |
| MLYS Mineralys Therapeutics | Reiterates: Buy | n/a | $13.74 | - | 2 | Feb 24, 2025 | |
| APGE Apogee Therapeutics | Reiterates: Buy | n/a | $41.18 | - | 7 | Feb 10, 2025 | |
| MRK Merck & Co. | Maintains: Buy | $137 → $130 | $79.29 | +63.96% | 13 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $38.64 | - | 2 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $61.41 | +13.99% | 1 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $5.67 | +182.19% | 1 | Oct 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.87 | - | 3 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $6.78 | - | 3 | Apr 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | n/a | $12.35 | - | 2 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $21.62 | +131.27% | 1 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $46.84 | - | 12 | Oct 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $74.01 | - | 2 | May 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $115.96 | - | 6 | Feb 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $6.35 | - | 1 | Feb 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $56 → $54 | $1.42 | +3,702.82% | 1 | Mar 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $60 → $45 | $20.82 | +116.14% | 3 | Mar 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $36 → $38 | $70.76 | -46.30% | 6 | Feb 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $35 → $38 | $23.88 | +59.13% | 3 | Jan 31, 2018 |
Cidara Therapeutics
May 16, 2025
Maintains: Buy
Price Target: $35 → $50
Current: $21.31
Upside: +134.63%
Eli Lilly and Company
Apr 14, 2025
Maintains: Buy
Price Target: $973 → $928
Current: $785.03
Upside: +18.21%
MBX Biosciences
Apr 10, 2025
Reiterates: Buy
Price Target: $44
Current: $10.28
Upside: +328.02%
Arcutis Biotherapeutics
Apr 3, 2025
Reiterates: Buy
Price Target: n/a
Current: $13.67
Upside: -
Verve Therapeutics
Mar 25, 2025
Reiterates: Buy
Price Target: n/a
Current: $11.12
Upside: -
Vaxcyte
Mar 12, 2025
Reiterates: Buy
Price Target: $160
Current: $33.41
Upside: +378.90%
Metsera
Feb 25, 2025
Initiates: Buy
Price Target: $56
Current: $27.71
Upside: +102.09%
Mineralys Therapeutics
Feb 24, 2025
Reiterates: Buy
Price Target: n/a
Current: $13.74
Upside: -
Apogee Therapeutics
Feb 10, 2025
Reiterates: Buy
Price Target: n/a
Current: $41.18
Upside: -
Merck & Co.
Nov 6, 2024
Maintains: Buy
Price Target: $137 → $130
Current: $79.29
Upside: +63.96%
Oct 31, 2024
Downgrades: Neutral
Price Target: n/a
Current: $38.64
Upside: -
Oct 21, 2024
Initiates: Buy
Price Target: $70
Current: $61.41
Upside: +13.99%
Oct 14, 2024
Initiates: Buy
Price Target: $16
Current: $5.67
Upside: +182.19%
Jul 8, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.87
Upside: -
Apr 29, 2024
Downgrades: Neutral
Price Target: n/a
Current: $6.78
Upside: -
Jul 14, 2023
Maintains: Buy
Price Target: n/a
Current: $12.35
Upside: -
Feb 28, 2023
Initiates: Buy
Price Target: $50
Current: $21.62
Upside: +131.27%
Oct 10, 2022
Downgrades: Neutral
Price Target: n/a
Current: $46.84
Upside: -
May 31, 2022
Upgrades: Buy
Price Target: n/a
Current: $74.01
Upside: -
Feb 25, 2020
Downgrades: Neutral
Price Target: n/a
Current: $115.96
Upside: -
Feb 3, 2020
Downgrades: Neutral
Price Target: n/a
Current: $6.35
Upside: -
Mar 13, 2018
Maintains: Outperform
Price Target: $56 → $54
Current: $1.42
Upside: +3,702.82%
Mar 8, 2018
Maintains: Market Perform
Price Target: $60 → $45
Current: $20.82
Upside: +116.14%
Feb 6, 2018
Maintains: Market Perform
Price Target: $36 → $38
Current: $70.76
Upside: -46.30%
Jan 31, 2018
Maintains: Market Perform
Price Target: $35 → $38
Current: $23.88
Upside: +59.13%